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Drug survival reﬂects a drug’s effectiveness, safety, and tolerability. We assessed the drug survival of biologics
used to treat psoriasis in a prospective national pharmacovigilance cohort (British Association of Dermatologists
Biologic Interventions Register (BADBIR)). The survival rates of the ﬁrst course of biologics for 3,523 biologic-
naive patients with chronic plaque psoriasis were compared using survival analysis techniques and predictors of
discontinuation analyzed using a multivariate Cox proportional hazards model. Data for patients on adalimumab
(n= 1,879), etanercept (n= 1,098), inﬂiximab (n= 96), and ustekinumab (n= 450) were available. The overall
survival rate in the ﬁrst year was 77%, falling to 53% in the third year. Multivariate analysis showed that female
gender (hazard ratio (HR) 1.22; 95% conﬁdence interval (CI): 1.09–1.37), being a current smoker (HR 1.19; 95% CI:
1.03–1.38), and a higher baseline dermatology life quality index (HR 1.01; 95% CI: 1.00–1.02) were predictors of
discontinuation. Presence of psoriatic arthritis (HR 0.82; 95% CI: 0.71–0.96) was a predictor for drug survival. As
compared with adalimumab, patients on etanercept (HR 1.63; 95% CI: 1.45–1.84) or inﬂiximab (HR 1.56; 95% CI:
1.16–2.09) were more likely to discontinue therapy, whereas patients on ustekinumab were more likely to persist
(HR 0.48; 95% CI: 0.37–0.62). After accounting for relevant covariates, ustekinumab had the highest ﬁrst-course
drug survival. The results of this study will aid clinical decision making when choosing biologic therapy for
psoriasis patients.
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INTRODUCTION
Biologic therapies have revolutionized the treatment of severe
psoriasis. Biologics currently licensed for psoriasis include the
tumor necrosis factor inhibitors (TNFIs)—adalimumab, eta-
nercept, and inﬂiximab––and an IL-12/IL-23 inhibitor—
ustekinumab. It has been established, however, that as a
general rule biologic therapies lose effectiveness over time
(Carrascosa et al., 2014a). There is a lack of clinical trial data
on the comparative effectiveness of the aforementioned
biologics. Moreover, the long-term safety and “real-world”
utility proﬁle of these novel drugs cannot be adequately
assessed in clinical trials, as trials are restricted by their
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inclusion criteria and size, being powered for primary efﬁcacy
outcomes, resulting in a low external validity for the “real-
world” psoriasis population (Garcia-Doval et al., 2012). The
clinical factors that inﬂuence the safety and effectiveness of
these novel agents are largely unknown.
Drug survival acts as a proxy marker of drug effectiveness,
safety, and real-world utility (Saad et al., 2009). An accurate
assessment of drug survival in the clinical setting will
help physicians choose the right drug, ﬁrst time for
patients, and thereby help health-care systems to be more
cost effective. Large-scale cohorts are required to fully
understand the factors inﬂuencing survival with these
novel drugs.
To date, seven studies have reported on the comparative
drug survival with biologics for psoriasis based on observa-
tional registries. Three of these studies have only reported on
drug survival with TNFIs (Gniadecki et al., 2011; Brunasso
et al., 2012; Esposito et al., 2013), whereas two involved the
same Danish national psoriasis biologic safety registry data
DERMBIO (Gniadecki et al., 2011, 2014), with the other
centers reporting data from either a single or a limited number
of centers (Umezawa et al., 2013; Menting et al., 2014;
van den Reek et al., 2014c). The British Association of
Dermatologists Biologic Interventions Register (BADBIR) is a
UK and Republic of Ireland prospective, longitudinal
pharmacovigilance register which represents an ideal
resource to assess real-world drug survival with biologics for
psoriasis due to its size, which allows for analysis of both
TNFIs and ustekinumab, a rigorous data collection process,
independent data analysis, inclusion of important covariates,
and high external validity through participation of multiple
dermatology centers (Burden et al., 2012). The aims of this
study were to establish which biologic is most likely to persist
in biologic-naive patients with psoriasis and to identify
clinically relevant risk factors for drug discontinuation.
RESULTS
Baseline demographics and disease characteristics
A total of 3,523 biologic-naive patients with at least 6 months
of follow-up data after initiation of biologic therapy were
included in the study from a data cut in August 2014
(Table 1). The mean (standard deviation (SD)) age of patients,
disease duration, and age of onset were 45.3 (12.8) years,
22.0 (12.4) years, and 23.3 (12.9) years, respectively, with
39.7% female. The mean (SD) body mass index (BMI) was
31.1 kg m− 2 (7.3), with 50% having a BMI 430 kgm−2.
Overall, 60.9% of patients had one or more comorbidities,
with hypertension (27.7%), depression (23.3%), and psoriatic
arthritis (PsA; 20.1%) being the most common. The most
common prescribed biologic was adalimumab: 1,879
(53.3%) patients. As expected, a higher proportion of patients
with PsA were on TNFIs as compared with ustekinumab
(Table 1).
Mean (SD) Psoriasis Area and Severity Index (PASI) and
Dermatology Life Quality Index (DLQI) scores at registration
were 15.9 (8.5) and 14.3 (8.9), respectively, with 13.7%
suffering from unstable psoriasis. The median, mean, and
range of the number of previous conventional systemic
therapies used for psoriasis were 2, 2.13, and 0–5,
respectively.
Drug survival with ﬁrst course of biologic therapy
Drug survival data for the ﬁrst course of biologic therapy were
available for a median (interquartile range), total follow-up,
and range of follow-up time of 1.4 (1.7), 5,955, and 0.5–6.9
person-years, respectively, with the median (interquartile
range) follow-up of patients receiving adalimumab being 1.3
(1.6) years, etanercept 1.5 (2.0), inﬂiximab 1.2 (1.6), and
ustekinumab 1.2 (0.9). There were 1,315 discontinuations of
treatment. Dosing data were investigated for adalimumab,
etanercept, and ustekinumab but not for the inﬂiximab cohort,
as the number of subjects (n= 96) was low. The standard
licensed dosing regimen for the above biologics are as
follows: 40mg every other week for adalimumab; 25 mg
twice weekly or 50mg once weekly for etanercept; and 45mg
12 weekly for ustekinumab if the patient’s weight is ≤ 100 kg
and 90mg 12 weekly if the patient’s weight is4100 kg. In all,
14% (n= 147) of patients on etanercept, 5.5% (n= 99) on
adalimumab, and 10.6% (n= 46) on ustekinumab had a
starting dose or dosing interval that was either higher
or shorter, respectively, than the standard licensed regimen
or had experienced an escalation in dose and/or reduction
in dosing interval during follow-up. The effect of dose escal-
ation was investigated through a sensitivity analysis as
detailed below.
Kaplan–Meier survival analyses (Table 2) Figure 1 revealed
an overall survival rate in the ﬁrst year of 77%, second year of
63%, and third year of 53%. In the ﬁrst year of therapy, 13%
of patients discontinued therapy due to ineffectiveness, 6%
due to adverse events (AEs), and 4% due to other reasons
(Table 2). Regarding the individual biologics, the ﬁrst year
survival rate for ustekinumab was 89%, adalimumab 79%,
etanercept 70%, and inﬂiximab 65%. The distribution of AEs
associated with drug discontinuation overall and for the
individual biologic therapies is shown in Table 3, with
infection being the most common AE experienced.
Predictors of drug survival with the ﬁrst course of biologic
therapy
Adalimumab was considered as the reference standard to
which the other biologic therapies were compared with
because it was the most commonly prescribed biologic in the
registry. The results from the univariate analysis are presented
in Table 4. The multivariate Cox model met the assumption of
proportionality globally. The overall multivariate model
showed that female gender (hazard ratio (HR) 1.22; 95%
conﬁdence interval (CI): 1.09–1.37), being a current smoker
(HR 1.19; 95% CI: 1.03–1.38), having a higher baseline DLQI
(HR 1.01; 95% CI: 1.00–1.02), and being on etanercept (HR
1.63; 95% CI: 1.45–1.84) or inﬂiximab (HR 1.56; 95% CI:
1.16–2.09) were predictors of discontinuation, whereas PsA
(HR 0.82; 95% CI: 0.71–0.96) and being on ustekinumab (HR
0.48; 95% CI: 0.37–0.62) were predictors of drug survival
(Table 4). For the model for discontinuation due to ineffec-
tiveness, BMI ≥ 35 kgm− 2 as compared with a normal-range
BMI, being a current smoker (HR 1.25; 95% CI: 1.02–1.54),
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and being on etanercept (HR 2.28; 95% CI: 1.93–2.69) were
predictors of discontinuation, whereas ustekinumab (HR 0.37;
95% CI: 0.25–0.57) was a predictor for drug survival. For the
model for discontinuation due to AEs, female gender (HR
1.79; 95% CI: 1.40–2.28) and being on inﬂiximab (HR 2.82;
95% CI: 1.79–4.45) were predictors for discontinuation,
whereas being on ustekinumab (HR 0.60; 95% CI: 0.39–
0.92) was a predictor for drug survival (Figure 2).
Sensitivity analysis was performed investigating the effects
of dose escalation. We stratiﬁed for the group of patients
with a standard licensed dosing regimen to investigate
whether dose escalation affected differential biologic drug
survival in our patient cohort. We did not ﬁnd a difference in
either the Kaplan–Meier plot or the multivariate regression
analysis between the overall patient population and the
patient population on standard licensed dosing with no dose
escalation, indicating that dose escalation did not alter
the differential individual biologic survival (Supplementary
Figure S1 and Supplementary Table S1 online). Another
sensitivity analysis investigated the impact of PsA with the
exclusion of the cohort of patients with concomitant PsA,
showing the same relative biologic drug survival as the overall
patient cohort. Other sensitivity analyses to investigate the
impact of missing dates of PASI and DLQI and the method of
missing data analysis were conducted to add robustness to the
results, with the differential overall drug survival with the
individual biologic therapies similar in all sensitivity analyses
models.
Table 1. The baseline demographic and disease characteristics of the study cohort
Demographic and disease characteristics
Characteristic
First biologic cohort
(n= 3,523)
Etanercept
(n=1,098, 31.2%)
Inﬂiximab
(n=96, 2.7%)
Adalimumab
(n=1,879, 53.3%)
Ustekinumab
(n= 450, 12.8%) P-value
Demographic (mean, SD for continuous variables; n, % cohort for categorical variables)
Age (years) 45.3 (12.8) 45.5 (13.0) 47.1 (12.9) 44.9 (12.6) 46.0 (13.0) 0.126
Female 1,400 (39.7%) 453 (41.3%) 30 (31.3%) 745 (39.7%) 172 (38.2%) 0.220
BMI category (kg m−2)
Underweight (o18.5) 32 (1.0%) 14 (1.4%) 1 (1.2%) 13 (0.8%) 4 (1.0%)
Normal (18.5–24.99) 559 (17.4%) 186 (18.8%) 16 (18.8%) 292 (16.9%) 65 (15.9%)
Overweight (25–29.99) 1,024 (31.9%) 316 (31.9%) 18 (21.2%) 568 (32.9%) 122 (29.8%)
Obese I (30–34.99) 788 (24.5%) 238 (24.0%) 18 (21.2%) 437 (25.3%) 95 (23.2%)
Obese II (35–39.99) 464 (14.4%) 154 (15.5%) 14 (16.5%) 238 (13.8%) 58 (14.2%)
Obese III (440) 346 (10.8%) 84 (8.5%) 18 (21.2%) 179 (10.4%) 65 (15.9%) 0.002
Current smoker 894 (30.0%) 252 (29.5%) 35 (41.7%) 485 (29.7%) 122 (30.1%) 0.018
Psoriatic arthritis 694 (20.1%) 216 (20.2%) 18 (19.2%) 401 (21.7%) 59 (13.3%) 0.001
No comorbidity1 1377 (39.1%) 412 (37.5%) 31 (32.3%) 768 (40.9%) 166 (36.9%)
1–2 Comorbidities1 1638 (46.5%) 536 (48.8%) 47 (49.0%) 855 (45.5%) 200 (44.4%)
3–4 Comorbidities1 436 (12.4%) 127 (11.6%) 15 (15.6%) 225 (12.0%) 69 (15.3%)
≥5 Comorbidities1 72 (2.0%) 23 (2.1%) 3 (3.1%) 31 (1.7%) 15 (3.3%) 0.056
Disease
Disease duration 22.0 (12.4) 22.3 (12.4) 21.6 (13.3) 21.7 (12.2) 22.2 (12.9) 0.577
Early onset (o40) 3,063 (87.6%) 949 (86.8%) 81 (84.4%) 1,642 (88.2%) 391 (87.5%) 0.713
Registration PASI 15.9 (8.5) 15.4 (7.9) 25.6 (11.7) 15.7 (8.3) 15.6 (8.9) o0.001
Registration DLQI 14.3 (8.9) 15.1 (8.4) 16.8 (10.1) 14.1 (9.0) 13.1 (9.1) o0.001
Unstable psoriasis 484 (13.7%) 142 (12.9%) 33 (34.4%) 245 (13.0%) 64 (14.2%) o0.001
Medication history
Baseline concomitant
methotrexate
327 (9.3%) 93 (8.5%) 17 (17.7%) 184 (9.8%) 33 (7.3%) 0.009
Baseline concomitant
ciclosporin
129 (3.7%) 49 (4.5%) 5 (5.2%) 59 (3.1%) 16 (3.6%) 0.250
Abbreviations: BMI, body mass index; DLQI, dermatology life quality index; PASI, psoriasis severity and area index.
P-value tests for signiﬁcant differences among the four biologic cohorts.
1Includes any of hypertension, angina, ischemic heart disease, stroke, pulmonary ﬁbrosis, asthma, chronic obstructive pulmonary disease, diabetes, thyroid
disease, peptic ulcers, hepatic disease, renal disease, demyelinating disease, epilepsy, depression, tuberculosis, and cancer. Bold: Po0.05.
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Table 2. The overall and differential biologic survival functions, stratiﬁed by reason for drug discontinuation, at
years 1, 2, and 3
Reasons for drug
discontinuation
First biologic
(n= 3,523)
Etanercept
(n=1,098)
Inﬂiximab
(n= 96)
Adalimumab
(n= 1,879)
Ustekinumab
(n=450)
All reasons
Year 1 0.77 (0.76–0.79) 0.70 (0.67–0.73) 0.65 (0.54–0.74) 0.79 (0.77–0.81) 0.89 (0.86–0.92)
Year 2 0.63 (0.61–0.65) 0.51 (0.48–0.54) 0.50 (0.39–0.60) 0.67 (0.65–0.70) 0.82 (0.76 –0.86)
Year 3 0.53 (0.51–0.55) 0.40 (0.37–0.44) 0.35 (0.24–0.47) 0.59 (0.56–0.62) 0.75 (0.68–0.81)
Ineffectiveness
Year 1 0.87 (0.86–0.88) 0.80 (0.77–0.82) 0.86 (0.76–0.92) 0.90 (0.88–0.91) 0.96 (0.93–0.97)
Year 2 0.78 (0.76–0.79) 0.65 (0.62–0.68) 0.79 (0.66–0.87) 0.83 (0.81–0.85) 0.93 (0.89–0.95)
Year 3 0.71 (0.69–0.73) 0.55 (0.52–0.59) 0.76 (0.63–0.85) 0.79 (0.76–0.82) 0.89 (0.82–0.93)
Adverse events
Year 1 0.94 (0.93–0.94) 0.94 (0.93–0.96) 0.84 (0.74–0.90) 0.93 (0.92–0.94) 0.96 (0.93–0.98)
Year 2 0.90 (0.89–0.92) 0.91 (0.89–0.93) 0.74 (0.62–0.83) 0.90 (0.88–0.92) 0.93 (0.90–0.96)
Year 3 0.88 (0.86–0.89) 0.90 (0.87–0.92) 0.59 (0.43–0.72) 0.87 (0.85–0.89) 0.91 (0.86–0.95)
Data presented as mean (95% conﬁdence interval).
Table 3. Adverse events leading to patient withdrawal by individual biologic therapy
Patient withdrawal due to adverse events
Adverse event leading to withdrawal (MedDRA
system organ classiﬁcation)
Etanercept
(n= 1,098)
Inﬂiximab
(n=96)
Adalimumab
(n= 1,879)
Ustekinumab
(n= 450)
Blood and lymphatic system disorders 0 0 2 (0.1%) 0
Cardiac disorders 0 0 3 (0.2%) 0
Ear and labyrinth disorders 0 0 0 0
Endocrine disorders 1 (0.1%) 0 0 0
Eye disorders 2 (0.2%) 0 1 (0.1%) 0
Gastrointestinal disorders 2 (0.2%) 2 (2.1%) 8 (0.4%) 4 (0.9%)
General disorders and administration site conditions 5 (0.5%) 3 (3.1%) 14 (0.7%) 1 (0.2%)
Hepatobiliary disorders 1 (0.1%) 2 (2.1%) 2 (0.1%0 0
Immune system disorders 2 (0.2%) 1 (1.0%) 0 0
Infections and infestations 10 (0.9%) 3 (3.1%) 25 (1.3%) 6 (1.3%)
Injury, poisoning, and procedural complications 0 3 (3.1%) 1 (0.1%) 0
Investigations 2 (0.2%) 2 (2.1%) 8 (0.4%) 1 (0.2%)
Metabolism and nutrition disorders 1 (0.1%) 0 0 0
Musculoskeletal and connective tissue disorders 1 (0.1%) 2 (2.1%) 9 (0.5%) 1 (0.2%)
Neoplasms benign, malignant, and unspeciﬁed (incl
cysts and polyps)
4 (0.4%) 0 4 (0.2%) 1 (0.2%)
Nervous system disorders 4 (0.4%) 0 7 (0.4%) 2 (0.4%)
Psychiatric disorders 1 (0.1%) 1 (1.0%) 1 (0.1%) 2 (0.4%)
Renal and urinary disorders 1 (0.1%) 0 2 (0.1%) 0
Reproductive system and breast disorders 1 (0.1%) 0 0 1 (0.2%)
Respiratory, thoracic, and mediastinal disorders 5 (0.5%) 3 (3.1%) 3 (0.2%) 0
Skin and subcutaneous tissue disorders 5 (0.5%) 1 (1.0%) 9 (0.5%) 2 (0.4%)
Vascular disorders 0 0 0 0
Total 48 23 99 21
Abbreviation: MedDRA, Medical Dictionary for Regulatory Activities.
Data presented as n (% of all patients in the biologic group).
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DISCUSSION
Current ﬁndings
This study represents the largest observational real-world
cohort study assessing the drug survival with biologics in
psoriasis to date. Our study focuses on biologic-naive patients
and shows that the survival with biologic therapies decreases
over time, from 77% in the ﬁrst year to 53% in the third year.
One of the most notable ﬁndings is that ustekinumab had a
signiﬁcantly higher survival rate than TNFIs, and this
difference persisted after controlling for clinical factors likely
Table 4. The univariate and multivariate Cox proportional hazard analysis for drug discontinuation, presented by
reason for withdrawal
Univariate and multivariate Cox proportional hazard analysis for drug discontinuation
Variable
Overall withdrawal Withdrawal due to ineffectiveness Withdrawal due to adverse events
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Demographics
Age 1.00 (0.99–1.00) 1.00 (0.99–1.01) 0.99* (0.98–1.00) 1.00 (0.99–1.01) 1.01* (1.00–1.02) 1.01 (1.00–1.03)
Female 1.28* (1.15–1.43) 1.22* (1.09–1.37) 1.11 (0.96–1.29) 1.02 (0.87–1.20) 1.74* (1.38–2.19) 1.79* (1.40–2.28)
BMI category (kg m−2)1
Underweight (o18.5) 1.61 (1.00–2.61) 1.30 (0.80–2.11) 1.59 (0.79–3.22) 1.27 (0.63–2.55) 1.00 (0.31–3.21) 0.69 (0.21–2.27)
Overweight (25–29.9) 0.90 (0.76–1.07) 0.98 (0.82–1.17) 1.03 (0.81–1.31) 1.13 (0.89–1.44) 0.82 (0.58–1.17) 0.86 (0.60–1.24)
Obese I (30–34.99) 0.92 (0.77–1.10) 1.01 (0.84–1.21) 1.12 (0.87–1.44) 1.23 (0.97–1.59) 0.66* (0.45–0.96) 0.67 (0.46–1.00)
Obese II (35–39.99) 1.07 (0.88–1.30) 1.12 (0.92–1.37) 1.34* (1.02–1.75) 1.44* (1.09–1.90) 0.82 (0.55–1.24) 0.79 (0.52–1.21)
Obese III (440) 1.07 (0.86–1.32) 1.15 (0.92–1.43) 1.22 (0.90–1.65) 1.48* (1.09–2.02) 0.89 (0.56–1.40) 0.76 (0.47–1.22)
Smoking status2
Ex-smoker 1.04 (0.89–1.20) 1.08 (0.93–1.26) 1.04 (0.85–1.28) 1.12 (0.91–1.39) 1.03 (0.75–1.43) 1.00 (0.72–1.38)
Current smoker 1.23* (1.06–1.42) 1.19* (1.03–1.38) 1.24* (1.02–1.51) 1.25* (1.02–1.54) 1.28 (0.94–1.76) 1.15 (0.83–1.59)
Comorbidities3
Psoriatic arthritis 0.87 [0.75–1.00) 0.82* [0.71–0.96) 0.87 [0.72–1.06) 0.83 (0.68–1.02) 1.04 (0.77–1.39) 1.02 (0.75–1.39)
1–2 Comorbidities 1.01 (0.90–1.13) 0.97 (0.86–1.10) 0.93 (0.79–1.09) 0.87 (0.74–1.03) 1.10 (0.85–1.42) 1.03 (0.79–1.34)
3–4 Comorbidities 1.07 (0.89–1.27) 1.09 (0.90–1.31) 1.01 (0.79–1.28) 1.01 (0.78–1.31) 1.18 (0.81–1.71) 1.04 (0.69–1.55)
≥5 Comorbidities 1.16 (0.80–1.69) 1.33 (0.90–1.96) 0.91 (0.52–1.59) 1.02 (0.57–1.82) 1.53 (0.75–3.15) 1.37 (0.65–2.90)
Disease
Disease duration 0.99* (0.99–1.00) 0.99 (0.99–1.00) 0.99* (0.98–1.00) 0.99 (0.98–1.00) 1.00 (0.99–1.01) 1.00 (0.98–1.01)
Early-onset disease (o40 years) 0.87 (0.72–1.06) 0.94 (0.74–1.21) 0.85 (0.65–1.11) 0.91 (0.65–1.27) 0.81 (0.54–1.21) 0.90 (0.54–1.51)
Registration PASI 1.01* (1.00–1.02) 1.01 (1.00–1.01) 1.01* (1.00–1.02) 1.01 (1.00–1.02) 1.02* (1.01–1.03) 1.01 (1.00–1.03)
Registration DLQI 1.02* (1.01–1.02) 1.01* (1.00–1.02) 1.02* (1.01–1.02) 1.01 (1.00–1.02) 1.02* (1.00–1.03) 1.01 (0.99–1.02)
Unstable psoriasis 1.19* (1.03–1.38) 1.13 (0.97–1.31) 1.18* (0.97–1.44) 1.19 (0.97–1.47) 1.27 (0.93–1.73) 1.03 (0.75–1.42)
Concomitant4 methotrexate 1.41* (1.20– 1.65) 1.33* (1.13– 1.57) 1.54* (1.25– 1.90) 1.49* (1.18– 1.88} 1.03 (0.71– 1.49) 0.94 (0.62– 1.43)
Concomitant4 ciclosporin 2.90* (2.41– 3.50) 2.60* (2.15– 3.15) 3.42* (2.70– 4.34) 3.08* (2.37– 4.00) 1.71* (1.06– 2.76) 1.66* (1.00– 2.75)
Biologic therapy5
Etanercept 1.74* (1.55–1.95) 1.63* (1.45–1.84) 2.43* (2.08–2.84) 2.28* (1.93–2.69) 0.79 (0.60–1.03) 0.77 (0.58–1.02)
Inﬂiximab 1.97* (1.49–2.61) 1.56* (1.16–2.09) 1.17 (0.70–1.97) 0.86 (0.51–1.47) 3.26* (2.14–4.97) 2.82* (1.79–4.45)
Ustekinumab 0.48* (0.38–0.62) 0.48* (0.37–0.62) 0.37* (0.25–0.56) 0.37* (0.25–0.57) 0.60* (0.39–0.92) 0.60* (0.39–0.92)
Abbreviations: BMI, body mass index; DLQI, dermatology life quality index; PASI, psoriasis severity and area index.
Data presented as hazard ratio (95% conﬁdence interval).
Drug year is adjusted for in the multivariate analysis.
*Po0.05, shown in bold.
1Reference category: normal BMI 18.5–24.9.
2Reference category: never smoked.
3Reference category: no comorbidities (excluding psoriatic arthritis); includes any of hypertension, ischemic heart disease, stroke, pulmonary ﬁbrosis, asthma,
chronic obstructive pulmonary disease, diabetes, thyroid disease, peptic ulcers, hepatic disease, renal disease, demyelinating disease, epilepsy, depression,
tuberculosis, and cancer.
4Time-varying covariates.
5Reference category: adalimumab.
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to cause systematic bias in biologic-naive patients. Of the
TNFIs, adalimumab had the highest survival rate in biologic-
naive patients. Important predictors for drug failure included
female gender, a higher registration DLQI, and current
smoking status, whereas patients with PsA persist with
biologic therapy longer than those without. As compared
with adalimumab, inﬂiximab was a predictor for discontinua-
tion overall and due to AEs, whereas etanercept was a
predictor for discontinuation both overall and due to
ineffectiveness.
Comparisons with current literature
The results of our study are broadly consistent with the
comparable published studies that considered drug survival
with both TNFI and ustekinumab in psoriasis. An updated
study from DERMBIO involving 1,277 psoriasis patients
treated with biologic therapy found that ustekinumab had
the highest survival rate with 81.9% at 4 years (Gniadecki
et al., 2014). A Dutch study from 8 regional centers of 213
patients found the 1-year survival rate of 85% for ustekinu-
mab, 74% for adalimumab, and 68% for etanercept, with a
multivariate analysis showing that ustekinumab had a
signiﬁcantly higher drug survival than etanercept but not
adalimumab (van den Reek et al., 2014c).
Due to the size and quality of baseline covariate data in our
study, we were able to robustly test whether the ﬁnding of
ustekinumab as the biologic therapy with the highest drug
survival represented a true ﬁnding or was a result of
systematic bias in the population. We studied a large
biologic-naive population, which negated any systematic
effect of prior biologic exposure on individual biologic drug
survival. We controlled for likely clinical factors that could
exert a confounding effect on the result, e.g., channeling bias
(the confounding effect of assigning certain treatments to
speciﬁc subgroups) through the concomitant prescription
of methotrexate and ciclosporin using a time-dependent
method. As drug survival with biologic therapy may also be
inﬂuenced by its dual efﬁcacy on psoriasis and PsA, we
explored the effect of PsA on the individual biologic survival.
A sensitivity analysis, using separate models with and without
the cohort with PsA, did not reveal a substantial change in the
differential individual biologic survival results. In addition, the
stratiﬁed model for the group of patients with a standard
licensed dosing regimen and no dose escalation against the
whole patient population also did not reveal a signiﬁcant
change to the differential biologic survival results (Supple-
mentary Figure S1, and Supplementary Table S1 online). The
low number of patients with dose escalation is likely to relate
to the system of public funding for these medications in the
United Kingdom, where applications for up-titration are often
not accepted.
The ustekinumab cohort in our study was twice the size of
the largest published study to date for the ﬁrst (n= 450) course
of therapy in biologic-naive patients, thereby giving the study
more power for the investigation of comparative biologic
survival. In addition, we included clinically relevant a priori
covariates for the multivariate analysis, whereas both
Gniadecki et al. (2014) and van den Reek et al. (2014c)
included only variables that were signiﬁcant in the univariate
analysis. This approach has the potential to miss important
effects of factors such as concomitant ciclosporin, smoking
status, and so on that, in combination with the lower study
numbers, may have accounted for the lack of signiﬁcant
difference found between ustekinumab and adalimumab in
the Dutch study. Importantly, Gniadecki et al. (2014) showed
in their study that the prevalence of PsA was higher in the
TNFI group as compared with the ustekinumab group, but this
was neither adjusted nor accounted for. Thus, the current
report represents the analysis of the largest cohort study
assessing biologic survival in biologic-naive psoriasis patients
to date, taking into account the effects of important clinically
relevant covariates.
Probable factors accounting for survival with biologics
Biologic survival reﬂects various factors including primary or
secondary drug effectiveness, drug safety and AE proﬁle, and
tolerability. Through our sensitivity analyses, we are conﬁdent
that the differences between the drug survival of the biologics
used to treat psoriasis are not explained by potential
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Figure 1. Crude drug survival of the ﬁrst biologic course showing
disaggregated biologic data (Kaplan–Meier survival curve).
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the overall multivariate Cox proportional hazard model in Table 4.
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confounders such as differential dosing escalation strategies
or difference in drug survival in the patients with concomitant
PsA. Possible reasons contributing to the higher drug survival
shown by ustekinumab as compared with the TNFIs, based on
the literature and known licensing information, are high
effectiveness (Grifﬁths et al., 2010), lower immunogenicity
(Carrascosa et al., 2014a), lower drug discontinuation due to
AEs (Table 4), dosing regimen, and method of administration.
Differences in the immunogenicity of the biologics
may affect survival rates, especially for withdrawals due to
ineffectiveness. A recent systematic review (Carrascosa et al.,
2014a) describes that antidrug antibodies are found in 4–46%
patients on adalimumab, 1.1–18.3% on etanercept, 19.5–
51.5% on inﬂiximab, and 3.8–5.1% in ustekinumab. In
addition, it has been shown that antidrug antibodies and
trough drug levels for adalimumab correlate with drug
effectiveness (Lecluse et al., 2010). The comparatively lower
proportion of antidrug antibodies seen in studies on
ustekinumab may partly explain the higher drug survival
with this biologic in this study, although it should be noted
that variations in reported antidrug antibody levels may partly
reﬂect the sensitivity of the different detection assays used.
A study into self-reported adherence to self-injectable
TNFIs in rheumatoid arthritis patients found that 27% of
patients had not taken the drug on the scheduled date on at
least one occasion in the ﬁrst 6 months of therapy (Bluett
et al., 2014). Crucially, this was associated with a lower
measured response following 6 months of therapy, suggesting
that nonadherence may have a role in the loss of effectiveness
of biologic therapies. The fact that ustekinumab is a 12-
weekly nurse-administered injection in most centers as
compared with the more frequent self-injection regimens for
other biologics may contribute to better drug adherence.
Consistent with the ﬁndings of our study, female gender has
been reported previously as a predictor of discontinuation of
biologics (Gniadecki et al., 2011, 2014; Esposito et al., 2013;
van den Reek et al., 2014a, b). Female gender is a predictor for
drug discontinuation in other conditions, such as hypertension
and postmyocardial infarction treatments (Franconi and
Campesi, 2014; Manteuffel et al., 2014), whereas women
with rheumatoid arthritis have lower remission rates for
treatment with TNFI therapy (Barnabe et al., 2014; Couderc
et al., 2014). Women also have a higher rate of severe AEs
(Davies et al., 2009; Pirmohamed et al., 2004).
We have shown that PsA is a predictor for overall drug
survival. Psoriatic arthritis has been found to be a predictor for
drug survival with TNFIs in one other observational study that
did not examine survival with ustekinumab (Brunasso et al.,
2012). As the severity of PsA and its response to treatment
were not captured in this study, this may represent a
confounding effect of the effectiveness of the biologic on
PsA. Although the sensitivity analysis for models with patients
with and without PsA showed that the HRs were similar,
further PsA-focused studies are needed before it could be
regarded as a genuine predictor for drug survival with biologic
therapies in psoriasis patients.
Our study reports that a BMI of 435 kgm−2 signiﬁcantly
predicted for drug discontinuation due to ineffectiveness. A
high BMI is a known predictor for discontinuation of biologics
(Naldi et al., 2008; Di Lernia et al., 2012; Edson-Heredia
et al., 2014; Carrascosa et al., 2014b). Ustekinumab is used in
two doses, 45 mg in patients weighing ≤ 100 kg and 90mg in
those 4100 kg, whereas adalimumab and etanercept are
used as ﬁxed doses irrespective of body weight. However, the
differential biologic survival did not change when the analysis
was restricted to patients o100 kgs (results not shown).
Consistent with previous studies showing poor treatment
response for TNFIs in psoriasis patients who were smokers, we
found that being a current smoker was a predictor for overall
discontinuation and for discontinuation due to ineffectiveness
(Di Lernia et al., 2014), whereas being an ex-smoker did not
predict for discontinuation, suggesting that an active smoking
status could affect the effectiveness of a biologic therapy.
Strengths and limitations
The major strengths of this study are the prospective real-
world cohort study design, the sample size, detailed data
capture allowing numerous covariates to be analyzed, fully
independent data analysis, and the multiple centers in the UK
and Republic of Ireland that, together, are unparalleled in
studies published to date. The wide inclusion criteria and the
participation of numerous centers across the UK and Republic
of Ireland (151 dermatology centers as of August 2014) ensure
high external validity. As BADBIR is constructed primarily as a
pharmacovigilance register, limitations to studying effective-
ness are inherent to the study design; e.g., the intention
behind concomitant medication, i.e., overlap, rescue, or
long term.
The accuracy of delineating the reason for drug withdrawal
is dependent on information from the recruiting dermatology
center. Recall and reporting bias may occur with patient-
reported characteristics. An inherent limitation in an observa-
tional study is nonrandomization that may introduce selection
bias, and although this is partially negated by adjustment for
clinically relevant covariables, the presence of unmeasured
confounders cannot be ruled out. Patient adherence was not
measured as part of this study. The inﬂiximab cohort is small
because of the stricter prescription criteria of this drug in most
of the United Kingdom, and hence the power of this cohort for
analysis is a particular concern. However, the inﬂiximab
cohort was recruited from 47 centers, with no concentration
at any one center and no speciﬁc concentration across a
particular region; hence, this cohort is likely to have high
external validity. Future analyses when BADBIR has matured
further may yield important data on second and subsequent
courses of biologics.
Summary
In summary, we have shown that biologics in clinical practice
have a good overall survival rate in psoriasis patients but
decrease over time, with loss of response being the main
determinant of discontinuation. After accounting for relevant
covariates, ustekinumab had the highest ﬁrst-course drug
survival in biologic-naive patients. Of the TNFIs, adalimumab
showed the highest survival rate in biologic-naive patients.
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The results of this study will aid clinical decision making
when choosing biologic therapy for psoriasis patients.
MATERIALS AND METHODS
Subjects were selected in a data snapshot from August 2014.
BADBIR, established in September 2007, compares a cohort of
psoriasis patients on biologics to a similar cohort on conventional
systemic therapies. A detailed report of the design of BADBIR has
been published previously (Burden et al., 2012). Of relevance to this
study, the NICE (National Institute for Health and Care Excellence), a
national guidance body, guidelines for the speciﬁc biologics include
the criteria of PASI ≥ 20 and DLQI 418 for the prescription of
inﬂiximab, and PASI ≥ 10 and DLQI 410 for the other biologics.
Guidelines in Scotland and the Republic of Ireland are similar.
Baseline assessment
Baseline data are collected with patient consent before or during the
initial 6 months of treatment. The classiﬁcations of disease
characteristics were determined by the treatment center physician.
Registration PASI and DLQI scores were taken at the time the patient
started the biologic therapy. The date of scoring was collected
following a protocol amendment in 2011.
Follow-up assessments
Data from patients are collected 6-monthly in the ﬁrst 3 years and
then annually thereafter. Details of the biologic therapies are
recorded, including any change in dose or therapy, gaps in treatment,
start and stop dates, and reasons for discontinuation. Patient
questionnaires are recorded to monitor for any hospital admissions,
new concomitant medications, and DLQI, whereas start and stop
dates of concomitant medications are recorded. Details of the AEs
were classiﬁed using the MedDRA (Medical Dictionary for Regula-
tory Activities) system (Bousquet et al., 2005).
Data analysis
Drug survival was deﬁned as the length of time from initiation to
discontinuation of therapy (Cramer et al., 2008). Discontinuation of
therapy was deﬁned as any gap in treatment for more than 90 days, to
disregard temporary or intermittent treatment due to clinical reasons,
e.g., infections or surgery, and takes into account the early UK
licensing prescription of etanercept in an intermittent regimen with
gaps of ˂90 days. The discontinuation date includes the earliest date
of any switchers to different biologics or death while registered on
BADBIR. This deﬁnition is in accordance with other drug survival
studies in psoriasis and psoriatic arthritis (Saad et al., 2009;
Gniadecki et al., 2011; Esposito et al., 2013; van den Reek et al.,
2014b).
The study inclusion criteria are biologic-naive patients with
chronic plaque psoriasis and at least one dermatologist’s follow-up
questionnaire, i.e., with follow-up data of ≥ 6 months, in the
biologics cohort. Differences in baseline characteristics between
the biologics were analyzed using analysis of variance for continuous
variables and the χ2 test for categorical variables (Table 1). Drug
survival was examined using Kaplan–Meier survival analysis, with
censorship occurring at the last available follow-up date. Reasons for
withdrawal, classiﬁed as due to ineffectiveness, AEs, and others, were
noted. AEs that were considered attributable to the drug by the
treatment center have been presented. For analysis of drug dosing
regimen, the standard licensed dosing regimens for the biologics that
were investigated were as follows: 40 mg every other week for
adalimumab; 25mg twice weekly or 50 mg once weekly for
etanercept; and 45mg 12 weekly for ustekinumab if the patient’s
weight is ≤ 100 kg and 90mg 12 weekly if the patient’s weight is
4100 kg. Any increase in the prescribed dose or decrease in the
dosing interval was considered to be dose escalations.
An a priori list of covariates was determined to address potential
predictors of discontinuation and as adjusters of potential confound-
ing (Table 4). BMI, derived from baseline measurements for height
and weight, was categorized according to the World Health
Organization classiﬁcation to maximize interpretability. The baseline
comorbidities were taken from a prespeciﬁed list and a free-text
section. Concomitant methotrexate and ciclosporin were analyzed as
time-varying covariates throughout the period of follow-up. The
covariates were entered for adjustment in the multivariate model but
not discussed because of the risk of channeling bias. The year of
biologic prescription was included for adjustment.
Multivariate Cox proportional hazard models were used to
ascertain predictive factors for the ﬁrst biologic course discontinua-
tion. The proportional hazard assumption was tested formally
using Schoenfeld residuals. Separate models were developed to
analyze overall discontinuation, discontinuation due to ineffective-
ness, and AEs. Patients were categorized as having an AE if they
either stopped therapy due to an AE or due to both an AE and
ineffectiveness.
A multiple imputation model of 20 cycles was performed to
account for missing data, the details of which are listed in
Supplementary Table S3 online. Sensitivity analyses that were
performed to add robustness to the results include a complete case
analysis model, a multiple-imputed model without the cohort with
PsA (Supplementary Table S1 online), a multiple-imputed multi-
variate model using the data of PASI and DLQI scores with a valid
date (post-2011 protocol modiﬁcation, Supplementary Table S2
online), and a multiple-imputed model with a cohort on a standard
dosing regimen and no dose escalation. Analyses were performed
using STATA version 13 (StataCorp, College Station, TX).
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